Direct‐acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The impact of sustained virologic response (SVR) on mortality after direct‐acting antiviral (DAA) treatment is not well documented in patients without advanced liver disease and affects access to treatment. This study evaluated the impact of SVR achieved with interferon‐free DAA treatment on all‐cause mortality in hepatitis C virus–infected patients without advanced liver disease. This observational cohort analysis was comprised of 103,346 genotype 1, 2, and 3, hepatitis C virus–monoinfected patients without advanced liver disease, defined by FIB‐4 ≤3.25 and no diagnosis of cirrhosis, hepatic decompensation, or hepatocellular carcinoma or history of liver transplantation, identified from the Veterans Affairs Hepatitis C Clinical Case Registry. Among 40,664 patients treated with interferon‐free DAA regimens, 39,374 (96.8%) achieved SVR and 1,290 (3.2%) patients were No SVR; 62,682 patients constituted the untreated cohort. The mortality rate for SVR patients of 1.18 deaths/100 patient‐years was significantly lower than the rates for both No SVR patients (2.84 deaths/100 patient‐years; P < 0.001) and untreated patients (3.84 deaths/100 patient‐years; P < 0.001). SVR patients with FIB‐4 <1.45 and 1.45‐3.25 had a 46.0% ( P = 0.036) and 63.2% ( P < 0.001) reduction in mortality rates, respectively, compared to No SVR patients and 66.7% ( P < 0.001) and 70.6% ( P < 0.001) reduction in mortality rates, respectively, compared to untreated patients. In multivariate Cox proportional hazard models controlling for baseline demographics, clinical characteristics, and comorbidities, SVR was independently associated with reduced risk of death compared to No SVR (hazard ratio, 0.44; 95% confidence interval, 0.32‐0.59; P < 0.001) and compared to untreated patients (hazard ratio, 0.32; 95% confidence interval, 0.29‐0.36; P < 0.001). Conclusion : Successfully treating hepatitis C virus with DAAs in patients without clinically apparent advanced liver disease translates into a significant mortality benefit. (H epatology 2018).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
Harris, T. B., Ferrucci, L., Tracy, R. P., Corti, M. C., Wacholder, S., Ettinger, W. H., Heimovitz, H., Cohen, H. J., & Wallace, R. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00066-2 · Cited by 1,488
Systemic Inflammation Predicts All-Cause Mortality: A Glasgow Inflammation Outcome Study
Proctor, M. J., McMillan, D. C., Horgan, P. G., Fletcher, C. D., Talwar, D., & Morrison, D. S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116206 · Cited by 168 · cited 1×
“A growing body of evidence supports the essential role of chronic HCV-related inflammation in the pathogenesis of hepatic and extrahepatic HCV-related disease,((35)) and increasing evidence links chronic inflammatory states with all-cause mortality.((36-39)) The relatively early appearance of an effect on mortality wh…”
Background
Cited by
Belli, L. S., Perricone, G., Adam, R., Cortesi, P. A., Strazzabosco, M., Facchetti, R., Karam, V., Salizzoni, M., Andujar, R. L., Fondevila, C., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.010 · Cited by 251
Baliashvili, D., Blumberg, H. M., Gandhi, N. R., Averhoff, F., Benkeser, D., Shadaker, S., Gvinjilia, L., Turdziladze, A., Tukvadze, N., Chincharauli, M., et al. (2023) · PLOS Medicine · doi:10.1371/journal.pmed.1004121
Metadata
- Authors
- Backus, L. I., Belperio, P. S., Shahoumian, T. A., & Mole, L. A.
- Venue
- Hepatology
- Published
- 2018-05-14
- Volume
- 68
- Issue
- 3
- Pages
- 827-838
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2794262809
- Cited by
- 160
- References
- 3
- FWCI
- 15.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Direct‐acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease. https://app.cochat.ai/papers/10.1002/hep.29811
- The paper
- Backus, L. I., Belperio, P. S., Shahoumian, T. A., & Mole, L. A. (2018). Direct‐acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease. Hepatology. https://doi.org/10.1002/hep.29811
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.